IDEAYA Biosciences (NASDAQ: IDYA) releases Q3 2025 financial results

Rhea-AI Filing Summary

IDEAYA Biosciences, Inc. furnished a current report describing that it announced its financial results for the third quarter ended September 30, 2025. The company did this through a press release dated November 4, 2025, which is included as Exhibit 99.1.

The report clarifies that the earnings information and the press release are being furnished, not filed, so they are not automatically subject to certain Exchange Act liabilities or incorporated into other securities law filings unless specifically referenced.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

Accepted by SEC EDGAR 11/04/2025 - 06:02 AM Learn about SEC filing dates

0001676725false00016767252025-11-042025-11-04

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 4, 2025

IDEAYA Biosciences, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-38915		47-4268251
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification Number)

5000 Shoreline Court, Suite 300

South San Francisco, California 94080
(Address of principal executive offices, including Zip Code)

Registrant’s telephone number, including area code: (650) 443-6209

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered or to be registered pursuant to Section 12(b) of the Act.

Title of each class		Trading Symbol		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		IDYA		The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On November 4, 2025, IDEAYA Biosciences, Inc. (the “Company”) announced its financial results for the third quarter ended September 30, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 2.02 and the attached Exhibit 99.1 are being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall they be deemed to be incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Press Release dated November 4, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		IDEAYA BIOSCIENCES, INC.
Date: November 4, 2025	By:	/s/ Yujiro Hata
		Yujiro Hata
		President and Chief Executive Officer

FAQ

What did IDEAYA Biosciences (IDYA) disclose in this 8-K?

IDEAYA Biosciences disclosed that it announced its financial results for the third quarter ended September 30, 2025, via a press release furnished as Exhibit 99.1.

Which period do the disclosed IDEAYA Biosciences (IDYA) results cover?

The results cover the third quarter ended September 30, 2025.

How did IDEAYA Biosciences (IDYA) provide its Q3 2025 financial results?

The company provided its Q3 2025 financial results in a press release dated November 4, 2025, which is attached to the report as Exhibit 99.1.

Are IDEAYA Biosciences' Q3 2025 results considered filed with the SEC?

The company states that the information in Item 2.02 and Exhibit 99.1 is being furnished and is not deemed filed for purposes of Section 18 of the Exchange Act.

Who signed the IDEAYA Biosciences (IDYA) 8-K regarding Q3 2025 results?

The report was signed on behalf of IDEAYA Biosciences, Inc. by Yujiro Hata, President and Chief Executive Officer, on November 4, 2025.

What exhibits are included with this IDEAYA Biosciences (IDYA) 8-K?

The report includes Exhibit 99.1, a press release dated November 4, 2025, and Exhibit 104, the Cover Page Interactive Data File embedded within the Inline XBRL document.